Vaccines 2016, 4(1), 2; doi:10.3390/vaccines4010002
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection
1
Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
2
Department of Microbiology, School of Basic Medical Sciences, Central South University, Changsha 410078, Hunan, China
*
Author to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Received: 17 November 2015 / Revised: 31 December 2015 / Accepted: 18 January 2016 / Published: 22 January 2016
View Full-Text
|
Download PDF [276 KB, uploaded 22 January 2016]
Abstract
HIV-1 virus-like particles (VLPs) are promising vaccine candidates against HIV-1 infection. They are capable of preserving the native conformation of HIV-1 antigens and priming CD4+ and CD8+ T cell responses efficiently via cross presentation by both major histocompatibility complex (MHC) class I and II molecules. Progress has been achieved in the preclinical research of HIV-1 VLPs as prophylactic vaccines that induce broadly neutralizing antibodies and potent T cell responses. Moreover, the progress in HIV-1 dendritic cells (DC)-based immunotherapy provides us with a new vision for HIV-1 vaccine development. In this review, we describe updates from the past 5 years on the development of HIV-1 VLPs as a vaccine candidate and on the combined use of HIV particles with HIV-1 DC-based immunotherapy as efficient prophylactic and therapeutic vaccination strategies. View Full-TextKeywords:
HIV-1; virus-like paticles (VLPs); vaccine; dendritic cells-based immunotherapy; adjuvants; dendritic cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Zhao, C.; Ao, Z.; Yao, X. Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines 2016, 4, 2.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Vaccines
EISSN 2076-393X
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert